GE

ThromboGenics publishes phase III data of ocriplasmin for VMT

Friday, August 17, 2012 03:11 PM

ThromboGenics, a Belgium-based biopharmaceutical company focused on ophthalmic medicines, has published data from two phase III clinical trials evaluating ocriplasmin for the treatment of Vitreomacular Adhesion (VMA) and macular holes in the New England Journal of Medicine.

More... »

Biogen Idec, Regulus to explore microRNA biomarkers for monitoring MS

Friday, August 17, 2012 11:38 AM

Regulus Therapeutics, a San Diego-based biopharmaceutical company focused on medicines targeting microRNAs, has entered into a collaboration with Biogen Idec to identify microRNAs as biomarkers for multiple sclerosis (MS).

More... »

HealthPartners, VitalSims partner to improve diabetes care

Wednesday, August 15, 2012 11:01 AM

HealthPartners, a not-for-profit health maintenance organization of Bloomington, Minn., and VitalSims, a healthcare education company of Minneapolis, Minn., are partnering to improve care for patients with chronic diseases through a joint venture, SiMCare Health.

More... »

FDA approves Lucentis for diabetic macular edema

Monday, August 13, 2012 10:33 AM

The FDA has approved Genentech’s Lucentis (ranibizumab injection) for the treatment of diabetic macular edema (DME), a sight-threatening eye disease that occurs in people with diabetes.

More... »

ADi awarded $2.5M SBIR grant to identify malaria protection biomarkers

Monday, August 13, 2012 10:13 AM

Antigen Discovery (ADi), a biotech based in Irvine, Calif., has received a phase II Small Business Innovation and Research (SBIR) award from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health.

More... »

Astellas to close Urogenix, shift urology research to Japan

Monday, August 6, 2012 02:09 PM

Astellas Pharma has decided to close Urogenix, an Astellas subsidiary and Durham, N.C.-based research facility focusing on drug discovery in the field of urology.

More... »

Prevention trial studies population 100% genetically predisposed to early-onset Alzheimer’s

Monday, August 6, 2012 07:00 AM

For the first time ever, an experimental drug is being tested to determine whether it can prevent Alzheimer’s disease in a population that has a 100% genetic predisposition for early onset of the disease. The study, to start next year, will be one of only a few being conducted to test prevention treatments for a genetically predestined disease.

More... »

Hologic completes acquisition of Gen-Probe

Thursday, August 2, 2012 02:17 PM

Hologic, a developer, manufacturer and supplier of diagnostic products, medical imaging systems and surgical products, has completed its acquisition of Gen-Probe, a developer of nucleic acid tests, for approximately $3.8 billion. Gen-Probe is now a wholly-owned subsidiary of Hologic.

More... »

New York Genome Center launches innovation center

Thursday, August 2, 2012 11:42 AM

New York Genome Center (NYGC), a non-profit engaged in a cooperative effort to transform medical research and clinical care, has launched its innovation center, which will provide access to new sequencing technologies and foster collaboration among NYGC’s institutional founding members (IFMs) and technology collaborators.

More... »

AmerisourceBergen signs 3 year supply agreement with Express Scripts

Thursday, August 2, 2012 09:56 AM

AmerisourceBergen, a global pharmaceutical services company based in Valley Forge, Penn., has signed a three year agreement to supply approximately $18.5 billion in pharmaceuticals to Express Scripts on an annual basis, effective October 1, 2012.

More... »